Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Neutrophil elastase enhances antigen presentation by upregulating human leukocyte antigen class I expression on tumor cells.
Chawla A, Alatrash G, Philips AV, Qiao N, Sukhumalchandra P, Kerros C, Diaconu I, Gall V, Neal S, Peters HL, Clise-Dwyer K, Molldrem JJ, Mittendorf EA. Chawla A, et al. Cancer Immunol Immunother. 2016 Jun;65(6):741-51. doi: 10.1007/s00262-016-1841-6. Epub 2016 Apr 29. Cancer Immunol Immunother. 2016. PMID: 27129972 Free PMC article.
The role of antigen cross-presentation from leukemia blasts on immunity to the leukemia-associated antigen PR1.
Alatrash G, Ono Y, Sergeeva A, Sukhumalchandra P, Zhang M, St John LS, Yang TH, Ruisaard K, Armistead PM, Mittendorf EA, He H, Qiao N, Rodriguez-Cruz T, Liang S, Clise-Dwyer K, Wieder ED, Lizee G, Lu S, Molldrem JJ. Alatrash G, et al. J Immunother. 2012 May;35(4):309-20. doi: 10.1097/CJI.0b013e31824b3b14. J Immunother. 2012. PMID: 22495388 Free PMC article.
Broad cross-presentation of the hematopoietically derived PR1 antigen on solid tumors leads to susceptibility to PR1-targeted immunotherapy.
Alatrash G, Mittendorf EA, Sergeeva A, Sukhumalchandra P, Qiao N, Zhang M, St John LS, Ruisaard K, Haugen CE, Al-Atrache Z, Jakher H, Philips AV, Ding X, Chen JQ, Wu Y, Patenia RS, Bernatchez C, Vence LM, Radvanyi LG, Hwu P, Clise-Dwyer K, Ma Q, Lu S, Molldrem JJ. Alatrash G, et al. J Immunol. 2012 Dec 1;189(11):5476-84. doi: 10.4049/jimmunol.1201221. Epub 2012 Oct 26. J Immunol. 2012. PMID: 23105141 Free PMC article.
A novel HLA-A*0201 restricted peptide derived from cathepsin G is an effective immunotherapeutic target in acute myeloid leukemia.
Zhang M, Sukhumalchandra P, Enyenihi AA, St John LS, Hunsucker SA, Mittendorf EA, Sergeeva A, Ruisaard K, Al-Atrache Z, Ropp PA, Jakher H, Rodriguez-Cruz T, Lizee G, Clise-Dwyer K, Lu S, Molldrem JJ, Glish GL, Armistead PM, Alatrash G. Zhang M, et al. Clin Cancer Res. 2013 Jan 1;19(1):247-57. doi: 10.1158/1078-0432.CCR-12-2753. Epub 2012 Nov 12. Clin Cancer Res. 2013. PMID: 23147993 Free PMC article.
A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells.
Ma Q, Garber HR, Lu S, He H, Tallis E, Ding X, Sergeeva A, Wood MS, Dotti G, Salvado B, Ruisaard K, Clise-Dwyer K, John LS, Rezvani K, Alatrash G, Shpall EJ, Molldrem JJ. Ma Q, et al. Cytotherapy. 2016 Aug;18(8):985-994. doi: 10.1016/j.jcyt.2016.05.001. Epub 2016 Jun 2. Cytotherapy. 2016. PMID: 27265873 Free PMC article.
61 results